NCT03663647 (ADMIRE) is a clinical trial in Cutaneous Melanoma, Stage IV, sponsored by MelanomaPRO, Russia.

Who is sponsoring NCT03663647?

NCT03663647 is sponsored by MelanomaPRO, Russia.

What condition does NCT03663647 study?

NCT03663647 studies Cutaneous Melanoma, Stage IV, BRAF V600 Mutation.

Is NCT03663647 still recruiting?

NCT03663647 is currently completed. Last updated 29 September 2021.

Last reviewed 2021-09-29 · How we verify

NCT03663647: ADMIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced Melanoma in Russian Experience

Completed Last updated 29 September 2021

What this trial tests

trial in Cutaneous Melanoma, Stage IV in 382 participants. Completed in 27 April 2019.

Timeline

8 October 2018

Primary endpoint
27 April 2019

27 April 2019

Quick facts

Lead sponsor	MelanomaPRO, Russia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	382
Start date	8 October 2018
Primary completion	27 April 2019
Estimated completion	27 April 2019
Sites	11 locations across Russia

Conditions studied

Cutaneous Melanoma, Stage IV — all drugs for Cutaneous Melanoma, Stage IV →
BRAF V600 Mutation — all drugs for BRAF V600 Mutation →

Sponsor

MelanomaPRO, Russia

Who can join

Adults 18 to 89, any sex, with Cutaneous Melanoma, Stage IV or BRAF V600 Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE).
Orlova KV, Ledin EV, Zhukova NV, Orlova RV, et al · · 2021 · cited 10× · PMID 34064013 · DOI 10.3390/cancers13112529

Verify or expand the search:

Other recruiting trials for Cutaneous Melanoma, Stage IV

Currently open trials in the same condition.

NCT07148245 — Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma · recruiting
NCT03719131 — Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy · Phase 2 · active not recruiting

Other MelanomaPRO, Russia trials

Trials by the same sponsor.

NCT05171374 — pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03663647 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MelanomaPRO, Russia
Last refreshed: 29 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03663647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing